AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF THE CLAIMS

1. (Cancelled).

2. (Cancelled).

3. (Cancelled).

4. (Cancelled).

5. (Cancelled).

6. (Cancelled).

7. (Cancelled).

8. (Cancelled).

9. (Cancelled).

10. (Cancelled).

11. (Cancelled).

12. (Cancelled).

13. (Twice Amended) A method for ameliorating a urination disorder comprising administering a composition comprising adrenomedullin wherein the urination disorder is a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.

14. (Cancelled).

15. (Cancelled).

16. (Previously Presented) A method according to claim 13, wherein the adrenomedullin is:

a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

17. (Previously Presented) A method according to claim 13, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ IS NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

18. (Previously Presented) A method according to claim 13, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Ala in position –73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

19. (Previously Presented) A method according to claim 13, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ IS NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

20. (Previously Presented) A method according to claim 13, wherein the C-terminus of the adrenomedullin is amidated.

21. (Previously Presented) A method according to claim 13, wherein Gly is added to the C-terminus of the adrenomedullin.

22. (Previously Presented) A method according to claim 13, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

23. (Previously Presented) A method according to claim 22, wherein the crosslink is a disulfide bond.

24. (Previously Presented) A method according to claim 22, wherein the crosslink is a $-CH_2-CH_2-$ bond.

25. (Previously Presented) A method for promoting passive extension of bladder smooth muscle comprising administering a composition comprising adrenomedullin.

26. (Previously Presented) A method according to claim 25, wherein the adrenomedullin is:

a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

27. (Previously Presented) A method according to claim 25, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

28. (Previously Presented) A method according to claim 25, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

29. (Previously Presented) A method according to claim 25, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

30. (Previously Presented) A method according to claim 25, wherein the C-terminus of the adrenomedullin is amidated.

31. (Previously Presented) A method according to claim 25, wherein Gly is added to the C-terminus of the adrenomedullin.

32. (Previously Presented) A method according to claim 25, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

33. (Previously Presented) A method according to claim 32, wherein the crosslink is a disulfide bond.

34. (Previously Presented) A method according to claim 32, wherein the crosslink is a $-CH_2-CH_2-$ bond.

35. (New) A method according to claim 25, whereby a urination disorder is ameliorated.

36. (New) A method according to claim 35, wherein the urination disorder is a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.